Actively Recruiting
Phase 3 Open-Label Extension Study of MHB018A Injection for Adults with Thyroid Eye Disease Evaluating Effectiveness and Safety in Patients Previously Treated with Placebo
Led by Minghui Pharmaceutical (Hangzhou) Ltd · Updated on 2026-03-30
258
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating MHB018A Injection in people with moderate-to-severe Thyroid Eye Disease TED in this multicenter, open-label extension study. The study aims to assess whether the treatment improves proptosis eye bulging compared to earlier baseline measurements and to monitor the safety and tolerability of MHB018A in participants who previously received placebo in related studies. This Phase III trial focuses on those with active or chronic TED and builds on prior research findings. Participants receive subcutaneous injections of MHB018A at a dose of 450 mg once every four weeks. This dosing continues throughout the open-label extension period, allowing researchers to observe longer-term effects and safety. The study includes subjects who completed an earlier 24-week double-blind treatment phase and met specific criteria related to response or relapse, with no planned corrective eye surgery or radiotherapy during the study. During the study, participants undergo regular assessments including measurements of proptosis, clinical activity scores, diplopia response, and quality of life related to eye disease. Safety monitoring tracks adverse events up to 24 weeks and at the end of the trial. Researchers also evaluate pharmacokinetics and relapse rates. Participants are expected to follow the treatment schedule and attend all evaluation visits over the study duration, which supports comprehensive data collection on the effects and safety of MHB018A.
CONDITIONS
Brief Title
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Research Team
C
CMO/ Senior Vice President of R&D
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here